Related Experiment Videos
[Teratogenesis and medication induced fetal toxicity].
Elisabeth Elefant1, Françoise Bavoux
1Centre de Renseignements sur les Agents Tératogènes (CRAT), Hôpital Armand Trousseau, 26, avenue du Dr Arnold Netter, 75571 Paris. elisabeth.elefant@trs.ap-hop-paris.fr
La Revue Du Praticien
|January 16, 2004
Summary
Treating pregnant women requires balancing medication risks and benefits. Multidisciplinary teams are crucial for safe pharmacotherapy, avoiding undertreatment or harmful strategies.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Teratology
Context:
- Pregnancy pharmacotherapy is a significant concern for healthcare providers and the public, historically influenced by events like thalidomide.
- Past alarmist approaches to medication use during pregnancy have evolved towards more evidence-based strategies.
- Understanding the risks of malformations and fetal toxicity from medications is critical.
Purpose:
- To advocate for a rational approach to pharmacotherapy in pregnant women.
- To promote a realistic risk:benefit assessment for treating sick pregnant individuals.
- To emphasize the importance of multidisciplinary collaboration in managing medication use during pregnancy.
Summary:
- A balanced risk:benefit evaluation is essential when considering pharmacological treatments for pregnant women.
- Avoiding undertreatment or maladaptive treatment is crucial, necessitating careful consideration of therapeutic options.
- Multidisciplinary team efforts are vital for optimizing pharmacotherapeutic strategies and preventing medical and human errors in managing pregnant patients, especially those with chronic conditions.
Impact:
- Encourages a shift from alarmist views to evidence-based decision-making in pregnancy pharmacotherapy.
- Supports the safe and effective management of maternal health conditions through appropriate medication use.
- Aims to improve patient outcomes by minimizing risks associated with drug exposure during gestation.